Neoplasms Clinical Trials

42 studies are recruiting for neoplasms in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Registry Study for Radiation Therapy Outcomes

   The purpose of this research study is to collect and analyze information from patients being treated with various forms of radiation therapy.

   Stage

   Not phased

   Ages

   Any age

   Site

   Mayo Clinic, Scottsdale, Arizona

   Locations

   29 in total

   Run by

   Proton Collaborative Group

   See if you can join NCT01255748 on ClinicalTrials.gov

2. A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

   The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount

   Stage

   Phase 1

   Ages

   18 and older

   Site

   GSK Investigational Site, Birmingham, Alabama

   Locations

   65 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06431594 on ClinicalTrials.gov

3. Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue

   Cancer-related fatigue affects at least 30-90% of patients with cancer, depending on the type of cancer and their treatment(s) (e.g., chemotherapy, radiation). It is not relieved by sleep or rest, and it sometimes can persist for years after a person's cancer was treated. The fatigue can be so bad …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Maryland, Baltimore, Baltimore, Maryland

   Run by

   University of Maryland, Baltimore

   See if you can join NCT06482515 on ClinicalTrials.gov

4. A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

   The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combinat…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   GSK Investigational Site, Stanford, California

   Locations

   67 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06551142 on ClinicalTrials.gov

5. Serious Gaming for Chemotherapy-induced Nausea and Vomiting

   The purpose of this study is to examine the effectiveness of a technology-based intervention for managing nausea and vomiting in older adults with cancer. Participants will be randomized to either an intervention or control group. Outcomes such as symptom severity, quality of life, and resource use…

   Stage

   Not phased

   Ages

   60 and older

   Site

   Miller School of Medicine Sylvester Comp. Cancer Center, Miami, Florida

   Locations

   2 in total

   Run by

   University of Central Florida

   See if you can join NCT05838638 on ClinicalTrials.gov

6. Cancer Experience Registry (CER) for Cancer Patients and Caregivers

   The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys. Study surveys are designed based on input from advisor experts, includ…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Cancer Support Community Research & Training Institute, Washington D.C., District of Columbia

   Run by

   Cancer Support Community, Research and Training Institute, Philadelphia

   See if you can join NCT02333604 on ClinicalTrials.gov

7. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

   This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of R…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Comprehensive Cancer Center, Duarte, California

   Locations

   21 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06884618 on ClinicalTrials.gov

8. A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

   This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Beijing Jishuitan Hospital, Beijing, Beijing Municipality

   Locations

   17 in total

   Run by

   Abbisko Therapeutics Co, Ltd

   See if you can join NCT04192344 on ClinicalTrials.gov

9. The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

   The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpos…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Allegheny Health Network, Pittsburgh, Pennsylvania

   Locations

   18 in total

   Run by

   UMC Utrecht

   See if you can join NCT04075305 on ClinicalTrials.gov

10. Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

    The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies.…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Stanford University School of Medicine, Stanford, California

    Run by

    Stanford University

    See if you can join NCT00349830 on ClinicalTrials.gov

11. A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

    The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    GSK Investigational Site, Lake Success, New York

    Locations

    6 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT07277270 on ClinicalTrials.gov

12. Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

    The purpose of this study is to examine the usefulness of implanting small 24-K gold fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify the original tumor location at the time of radiation treatment. Other goals of the study include assessing whether a new MRI…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center (CSMC), Los Angeles, California

    Locations

    3 in total

    Run by

    Cedars-Sinai Medical Center

    See if you can join NCT04442724 on ClinicalTrials.gov

13. 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

    This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT) at the West Los Angeles VA (WLA-VA) will be imaged with a baseline F…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    VA Greater Los Angeles Healthcare System, Los Angeles, California

    Run by

    VA Greater Los Angeles Healthcare System

    See if you can join NCT06706921 on ClinicalTrials.gov

14. Barrett's Esophagus Related Neoplasia (BERN) Project

    * The use of high resolution endoscopy (HRE), narrow band imaging (NBI) and chromoendoscopy increases the detection rates of Barrett's esophagus (BE) and early neoplasia. * Endoscopic mucosal resection (EMR) will improve the accuracy for detection of dysplasia/early neoplasia. Specific Aim 1 - To c…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Kansas city VA Medical center, Kansas City, Missouri

    Run by

    Midwest Biomedical Research

    See if you can join NCT00590239 on ClinicalTrials.gov

15. RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

    The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most effective use of these systems in management of patients wit…

    Stage

    Not phased

    Ages

    Any age

    Site

    Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida

    Locations

    13 in total

    Run by

    The Radiosurgery Society

    See if you can join NCT01885299 on ClinicalTrials.gov

16. A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

    The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Northside Hospital, Atlanta, Georgia

    Run by

    OriCell Therapeutics Co., Ltd.

    See if you can join NCT06271252 on ClinicalTrials.gov

17. AIMS Cancer Outcomes Study

    The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect …

    Stage

    Not phased

    Ages

    Any age

    Site

    AIMS Institute, Seattle, Washington

    Run by

    Advanced Integrative Medical Science Institute

    See if you can join NCT04495790 on ClinicalTrials.gov